Table 3.
Comparison of in-hospital pharmacological treatments for UK, European, and multinational groups of patients by baseline condition
| ST elevation MI | p Value | Non-ST elevation MI | p Value | Unstable angina | p Value | ||||||||||
| UK (n = 390) | Eur (n = 2729) | MN (n = 3696) | UK v Eur | UK v MN | UK (n = 376) | Eur (n = 160)2 | MN (n = 4111) | UK v Eur | UK v MN | UK (n = 605) | Eur (n = 2174) | MN (n = 4457) | UK v Eur | UK v MN | |
| Aspirin | 96% | 94% | 95% | 0.1021 | 0.4041 | 94% | 91% | 92% | 0.0685 | 0.6897 | 92% | 90% | 92% | 0.1300 | 0.8024 |
| Thienopyridine | 18% | 48% | 40% | <0.0001 | <0.0001 | 31% | 44% | 31% | <0.0001 | 0.8125 | 25% | 29% | 25% | 0.0416 | 0.8229 |
| β Blocker | 82% | 79% | 86% | 0.1093 | 0.0532 | 78% | 77% | 83% | 0.7849 | 0.0036 | 73% | 72% | 79% | 0.6805 | 0.0003 |
| Ca2+ Blocker | 16% | 12% | 16% | 0.0268 | 0.9880 | 40% | 25% | 29% | 0.0268 | <0.0001 | 52% | 39% | 35% | <0.0001 | <0.0001 |
| GP IIb/IIIa | 6% | 31% | 28% | <0.0001 | <0.0001 | 6% | 25% | 26% | <0.0001 | <0.0001 | 3% | 7% | 11% | <0.0001 | <0.0001 |
| LMWH | 35% | 62% | 29% | <0.0001 | 0.0159 | 74% | 83% | 39% | <0.0001 | <0.0001 | 68% | 68% | 34% | 0.4799 | <0.0001 |
| Unfractionated heparin | 67% | 58% | 73% | 0.0003 | 0.0223 | 34% | 45% | 66% | 0.0003 | <0.0001 | 26% | 30% | 56% | 0.0526 | <0.0001 |
| ACEI | 56% | 68% | 70% | <0.0001 | <0.0001 | 48% | 59% | 57% | <0.0001 | 0.0060 | 35% | 56% | 51% | <0.0001 | <0.0001 |
| Statin | 73% | 58% | 43% | <0.0001 | <0.0001 | 67% | 54% | 45% | <0.0001 | <0.0001 | 61% | 47% | 45% | <0.0001 | <0.0001 |